There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Travere Therapeutics (TVTX) and Glaukos (GKOS) with bullish sentiments. According to TipRanks.com, Rama ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled ...

Travere Therapeutics Inc, a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease, announced ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes") ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”) ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 ...

Travere Therapeutics missed EPS and revenue forecasts for Q1 2026. Stock price increased by 1.81% in aftermarket trading. Filspari sales showed strong year-over-year growth. The company achieved ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.